Towards Setting Minimum and Optimal Data to Report for Malaria Molecular Surveillance with Targeted Sequencing: The “What” and the “Why”
Authors:
- Jonathan JulianoJJJonathan Juliano
- Cecile Meier-ScherlingCMCecile Meier-Scherling
- Neeva Wernsman YoungNYNeeva Wernsman Young
- George TollefsonGTGeorge Tollefson
- Sean ConnellySCSean Connelly
- Jonathan ParrJPJonathan Parr
- Melissa ConradMCMelissa Conrad
- Jacob SadlerJSJacob Sadler
- Christopher HennellyCHChristopher Hennelly
- Ashenafi AssefaAAAshenafi Assefa
- Lucy OkellLOLucy Okell
- Abebe FolaAFAbebe Fola
Preprint
- 21 July 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
The COVID-19 pandemic showcased the power of genomic surveillance in tracking infectious diseases, driving rapid public health responses, and global collaboration. This same infrastructure is being leveraged for malaria molecular surveillance (MMS) in Africa to tackle challenges like artemisinin partial resistance and Plasmodium falciparum histidine-rich protein 2 and 3 gene deletions. However, variability in reporting sequencing methods and data reporting is currently limiting the validation, comparability, and reuse of data. To maximize the impact of MMS, we propose minimal and optimal data for reporting that are key for validation and maximize transparency and FAIR (Findable, Accessible, Interoperable, Reusable) principles. Rather than focusing on specific data formats, here, we propose what should be reported and why. Moving to reporting individual infection-level polymorphism or microhaplotype data is central to maximizing the impact of MMS. Reporting must adhere to local regulatory practices and ensure proper data oversight and management, preventing data colonialism and preserving opportunities for data generators. With malaria’s challenges transcending borders, reporting and adopting standardized practices are essential to advance research and strengthen global public health efforts.Keywords
All Related Versions
This publication has 58 references indexed in Scilit:
- Prevalence of mutations associated with artemisinin partial resistance and sulfadoxine–pyrimethamine resistance in 13 regions in Tanzania in 2021: a cross-sectional surveyThe Lancet Microbe, 2024
- Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistanceThe Lancet Infectious Diseases, 2024
- Molecular markers for malaria genetic epidemiology: progress and pitfallsTrends in Parasitology, 2023
- Multiplexed ddPCR-amplicon sequencing reveals isolated Plasmodium falciparum populations amenable to local elimination in Zanzibar, TanzaniaNature Communications, 2023
- Inference of person-to-person transmission of COVID-19 reveals hidden super-spreading events during the early outbreak phaseNature Communications, 2020
- Analysis of Genomic Characteristics and Transmission Routes of Patients With Confirmed SARS-CoV-2 in Southern California During the Early Stage of the US COVID-19 PandemicJAMA Network Open, 2020
- Optimal Control of the COVID-19 Pandemic with Non-pharmaceutical InterventionsBulletin of Mathematical Biology, 2020
- The impact of antimalarial resistance on the genetic structure of Plasmodium falciparum in the DRCNature Communications, 2020
- DADA2: High-resolution sample inference from Illumina amplicon dataNature Methods, 2016
- Ahead of the curve: next generation estimators of drug resistance in malaria infectionsTrends in Parasitology, 2013